Metropolis Healthcare Ltd Q4 FY26: Revenue Surges 23% to ₹425 Cr as Mega Bonus 3:1 Signals Dominance

At a Glance

The Indian diagnostic landscape is witnessing a brutal shift where “unreasonable capital” is dying, and Metropolis Healthcare is moving in for the kill. The numbers for Q4 FY26 aren’t just growth figures; they are a declaration of war against fragmented, unorganized players. With a Market Cap of ₹10,942 Cr, Metropolis has reported a quarterly revenue of ₹425 Cr, a staggering 23% YoY jump.

But don’t let the top-line gloss fool you into complacency. The company is navigating a complex web of high-stakes acquisitions—Core Diagnostics, DAPIC, and Scientific Pathology—which, while expanding the footprint into North India, act as a temporary drag on margins. The “Group” EBITDA margin sits at 25.4%, but when you peel back the layers to the “Organic” business, it hits a leaner 27.2%. This gap is the price of expansion.

Metropolis is aggressively pivoting from a B2B dependency to a B2C powerhouse, now commanding 60% of organic revenue from direct consumers. This is a deliberate move to escape the “receivable trap” of institutional business. However, the shadow of North India integration looms large. While revenue from the North has doubled from 9% to 17%, the operational integration of Core Diagnostics is a high-wire act that management must finish by Q1 FY27.

Investors are cheering the 3:1 Bonus Issue, but the real story lies in the Genomics pivot. With the Delhi Genomics Centre now live, Metropolis is betting that high-end molecular testing will insulate them from the price wars of routine blood tests. The question remains: can they maintain this pace without sacrificing the “Stable” rating they recently fought to protect?

Introduction

Metropolis Healthcare stands as the second-largest diagnostic titan in India, a position it has guarded through a mix of ruthless expansion and high-end scientific differentiation. Operating across 750 towns with a network of 212 clinical labs and over 5,026 service points, it has built a “moat” of doctor trust and technical accreditation (CAP and NABL).

The company’s DNA is currently undergoing a structural mutation. Historically a king in the West and South, Metropolis is now aggressively “planting flags” in the North and East through inorganic acquisitions. This isn’t just about adding labs; it’s about specialized testing. With 4,000+ tests and profiles, they are moving away from the commodity “routine” market toward “Specialty” and “TruHealth” wellness segments.

The management has been vocal about the end of “discount-led growth” in the industry. They are focusing on Revenue Per Patient (RPP), which has climbed to ₹1,143 for the organic business. As they integrate five recent acquisitions, the focus is shifting from “adding labs” to “extracting productivity.”

Business Model – WTF Do They Even Do?

Metropolis sells “assurance” in the form of diagnostic reports. They operate on a Hub-and-Spoke model. The massive Global Reference Lab in Mumbai acts as the brain, while regional labs and thousands of collection centers act as the nervous system, feeding samples back for specialized analysis.

Their revenue is split into four buckets:

• Routine (17%): Your basic blood sugar and cholesterol tests. Low margin, high competition.
• Semi-Special (26%): Slightly more complex stuff.
• Specialty (40%): The high-margin gold mine involving Oncology, Neurology, and Genomics.
• TruHealth (17%): Preventive wellness packages—this is where they upsell to health-conscious millennials.

They’ve smartly moved toward an asset-light model, where 92% of their central network is leased or franchised. This keeps the Balance Sheet from getting bloated with real estate, allowing them to focus on expensive medical hardware instead.

Financial Wisdom: In a crowded market, the brand that controls the “Prescribing Doctor’s Trust” wins over the one that offers the cheapest price. Quality is a moat that discounts cannot bridge.

Financials Overview

The latest results show a clear divergence between the “Old Metropolis” (Organic) and the “New Metropolis” (including acquisitions).

Export to Sheets

*Note: YoY EBITDA growth is magnified due to one-time acquisition expenses of ₹21 Cr in the previous year’s base.